Literature DB >> 10764658

Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms.

G P Rossi1, A Sacchetto, D Rizzoni, S Bova, E Porteri, G Mazzocchi, A S Belloni, M Bahcelioglu, G G Nussdorfer, A C Pessina.   

Abstract

We investigated the role of angiotensin II (Ang II) and endothelin-1 (ET-1) in transgenic (mREN2)27 rats, a model of the monogenic renin-dependent form of severe hypertension and cardiovascular disease. Four-week-old heterozygous male transgenic (mREN2)27 rats (n=24) were matched according to body weight (BW) and blood pressure (BP) and randomly allocated to receive a placebo (group P), the mixed endothelin type A and B receptor antagonist bosentan (100 mg/kg BW PO, group B), the Ang II type 1-specific receptor antagonist irbesartan (50 mg/kg BW PO, group I), or the endothelin type A-selective antagonist BMS-182874 (52 mg/kg BW PO, group BMS). After 4 weeks of treatment, during which BW and BP were measured weekly, animals were euthanized, and the heart, left ventricle, right ventricle, adrenal gland, brain, and kidney were weighed. The plasma levels of adrenocortical steroids were measured by high-performance liquid chromatography. The tension responses of ET-free segments of the thoracic aorta to 5 x 10(-6) mmol/L phenylephrine, 60 mmol/L KCl, and cumulative doses of ET-1 were assessed. The density of ET-1 receptor subtypes in the aorta and vascular structural changes in the mesenteric arterioles (100 to 200 microm ID) were also measured with autoradiography and myography, respectively. Compared with all other groups, group I rats showed significantly (P<0.001) lower systolic BP (group I, 161+/-8 mm Hg; group P, 269+/-23 mm Hg; group B, 275+/-17 mm Hg; and group BMS, 254+/-21 mm Hg), left ventricular weight (2.28+/-0.15 versus 3. 71+/-0.26, 3.38+/-0.27, and 3.96+/-0.51 mg/g BW, respectively), tension responses to vasoconstrictors, and normalized media thickness of the mesenteric arterioles (22.3+/-0.6 versus 25.3+/-0.5, 25.5+/-0.7, and 24.1+/-1.5 microm, respectively). Compared with levels in group P (78+/-25 pmol/mL), plasma aldosterone levels were significantly decreased in group B (51+/-11 pmol/mL) and group I (40+/-16 pmol/mL). Thus, endogenous ET-1 and Ang II contribute to the regulation of aldosterone, but only Ang II is crucial for the development of hypertension and related target organ damage via the Ang II type 1 receptor. Endogenous Ang II does not appear to enhance cardiovascular production of ET-1 in this model of hypertension within the time span of our experiment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764658     DOI: 10.1161/01.atv.20.4.949

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  8 in total

1.  Association between the molecular pathobiology of essential hypertension and thrombotic diseases.

Authors:  T S Edgington
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

2.  Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice: role of endothelin-1.

Authors:  Y Suzuki; O Lopez-Franco; D Gomez-Garre; N Tejera; C Gomez-Guerrero; T Sugaya; R Bernal; J Blanco; L Ortega; J Egido
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

3.  NFAT is required for spontaneous pulmonary hypertension in superoxide dismutase 1 knockout mice.

Authors:  Juan Manuel Ramiro-Diaz; Carlos H Nitta; Levi D Maston; Simon Codianni; Wieslawa Giermakowska; Thomas C Resta; Laura V Gonzalez Bosc
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-03-08       Impact factor: 5.464

4.  Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta.

Authors:  James M Luther; Zuofei Wang; Ji Ma; Natalia Makhanova; Hyung-Suk Kim; Nancy J Brown
Journal:  Endocrinology       Date:  2008-12-23       Impact factor: 4.736

5.  Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat.

Authors:  Adam Whaley-Connell; Javad Habibi; Shawna A Cooper; Vincent G Demarco; Melvin R Hayden; Craig S Stump; Daniel Link; Carlos M Ferrario; James R Sowers
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-05-06       Impact factor: 4.310

6.  Elevated mean arterial pressure in the ovariectomized rat was normalized by ET(A) receptor antagonist therapy: absence of cardiac hypertrophy and fibrosis.

Authors:  Isabelle Mercier; Mylan Pham-Dang; Robert Clement; Hugues Gosselin; Federico Colombo; Jean-Lucien Rouleau; Angelino Calderone
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

Review 7.  Endothelium and its alterations in cardiovascular diseases: life style intervention.

Authors:  Gaia Favero; Corrado Paganelli; Barbara Buffoli; Luigi Fabrizio Rodella; Rita Rezzani
Journal:  Biomed Res Int       Date:  2014-02-26       Impact factor: 3.411

8.  Endothelin-1 Drives Epithelial-Mesenchymal Transition in Hypertensive Nephroangiosclerosis.

Authors:  Teresa M Seccia; Brasilina Caroccia; Francesca Gioco; Maria Piazza; Valentina Buccella; Diego Guidolin; Eugenia Guerzoni; Barbara Montini; Lucia Petrelli; Elisa Pagnin; Verdiana Ravarotto; Anna S Belloni; Lorenzo A Calò; Gian Paolo Rossi
Journal:  J Am Heart Assoc       Date:  2016-07-21       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.